A retrospective medical records review of risk factors for the development of respiratory tract secretions (death rattle) in the dying patient

Hildegard Kolb, Austyn Snowden, Elaine Stevens, Iain Atherton

Research output: Contribution to journalArticle

70 Downloads (Pure)

Abstract

Aim: Identification of risk factors predicting the development of death rattle.

Background: Respiratory tract secretions, often called death rattle, are among the most common symptoms in dying patients around the world. It is unknown whether death rattle causes distress in patients, but it has been globally reported that distress levels can be high in family members. Although there is a poor evidence base, treatment with antimuscarinic medication is standard practice worldwide and prompt intervention is recognized as crucial for effectiveness. The identification of risk factors for the development of death rattle would allow for targeted interventions.

Design: A case–control study was designed to retrospectively review two hundred consecutive medical records of mainly cancer patients who died in a hospice inpatient setting between 2009–2011. Fifteen potential risk factors including the original factors weight, smoking, final opioid dose and final midazolam dose were investigated.

Methods: Binary logistic regression to identify risk factors for death rattle development.

Results: Univariate analysis showed death rattle was significantly associated with final Midazolam doses and final opioid doses, length of dying phase and anticholinergic drug load in the pre-terminal phase. In the final logistic regression model only Midazolam was statistically significant and only at final doses of 20 mg/24 hrs or over (OR 3.81 CI 1.41–10.34).

Conclusions: Dying patients with a requirement for a high dose of Midazolam have an increased likelihood of developing death rattle.
Original languageEnglish
Pages (from-to)1639-1648
Number of pages9
JournalJournal of Advanced Nursing
Volume74
Issue number7
Early online date9 May 2018
DOIs
Publication statusPublished - 1 Jul 2018

Fingerprint

Respiratory System
Medical Records
Midazolam
Logistic Models
Opioid Analgesics
Hospices
Muscarinic Antagonists
Cholinergic Antagonists
Inpatients
Cause of Death
Smoking
Weights and Measures
Pharmaceutical Preparations
Neoplasms

Keywords

  • bronchial secretions, cholinergic antagonists, death rattle, midazolam, nursing, palliative care, respiratory signs and symptoms, respiratory sounds, risk factors, terminal care

Cite this

@article{979dab077f854d999988c76efcec1473,
title = "A retrospective medical records review of risk factors for the development of respiratory tract secretions (death rattle) in the dying patient",
abstract = "Aim: Identification of risk factors predicting the development of death rattle.Background: Respiratory tract secretions, often called death rattle, are among the most common symptoms in dying patients around the world. It is unknown whether death rattle causes distress in patients, but it has been globally reported that distress levels can be high in family members. Although there is a poor evidence base, treatment with antimuscarinic medication is standard practice worldwide and prompt intervention is recognized as crucial for effectiveness. The identification of risk factors for the development of death rattle would allow for targeted interventions.Design: A case–control study was designed to retrospectively review two hundred consecutive medical records of mainly cancer patients who died in a hospice inpatient setting between 2009–2011. Fifteen potential risk factors including the original factors weight, smoking, final opioid dose and final midazolam dose were investigated. Methods: Binary logistic regression to identify risk factors for death rattle development.Results: Univariate analysis showed death rattle was significantly associated with final Midazolam doses and final opioid doses, length of dying phase and anticholinergic drug load in the pre-terminal phase. In the final logistic regression model only Midazolam was statistically significant and only at final doses of 20 mg/24 hrs or over (OR 3.81 CI 1.41–10.34).Conclusions: Dying patients with a requirement for a high dose of Midazolam have an increased likelihood of developing death rattle.",
keywords = "bronchial secretions, cholinergic antagonists, death rattle, midazolam, nursing, palliative care, respiratory signs and symptoms, respiratory sounds, risk factors, terminal care",
author = "Hildegard Kolb and Austyn Snowden and Elaine Stevens and Iain Atherton",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/jan.13704",
language = "English",
volume = "74",
pages = "1639--1648",
journal = "Journal of Advanced Nursing",
issn = "0309-2402",
publisher = "Wiley",
number = "7",

}

A retrospective medical records review of risk factors for the development of respiratory tract secretions (death rattle) in the dying patient. / Kolb, Hildegard; Snowden, Austyn; Stevens, Elaine; Atherton, Iain.

In: Journal of Advanced Nursing, Vol. 74, No. 7, 01.07.2018, p. 1639-1648.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A retrospective medical records review of risk factors for the development of respiratory tract secretions (death rattle) in the dying patient

AU - Kolb, Hildegard

AU - Snowden, Austyn

AU - Stevens, Elaine

AU - Atherton, Iain

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Aim: Identification of risk factors predicting the development of death rattle.Background: Respiratory tract secretions, often called death rattle, are among the most common symptoms in dying patients around the world. It is unknown whether death rattle causes distress in patients, but it has been globally reported that distress levels can be high in family members. Although there is a poor evidence base, treatment with antimuscarinic medication is standard practice worldwide and prompt intervention is recognized as crucial for effectiveness. The identification of risk factors for the development of death rattle would allow for targeted interventions.Design: A case–control study was designed to retrospectively review two hundred consecutive medical records of mainly cancer patients who died in a hospice inpatient setting between 2009–2011. Fifteen potential risk factors including the original factors weight, smoking, final opioid dose and final midazolam dose were investigated. Methods: Binary logistic regression to identify risk factors for death rattle development.Results: Univariate analysis showed death rattle was significantly associated with final Midazolam doses and final opioid doses, length of dying phase and anticholinergic drug load in the pre-terminal phase. In the final logistic regression model only Midazolam was statistically significant and only at final doses of 20 mg/24 hrs or over (OR 3.81 CI 1.41–10.34).Conclusions: Dying patients with a requirement for a high dose of Midazolam have an increased likelihood of developing death rattle.

AB - Aim: Identification of risk factors predicting the development of death rattle.Background: Respiratory tract secretions, often called death rattle, are among the most common symptoms in dying patients around the world. It is unknown whether death rattle causes distress in patients, but it has been globally reported that distress levels can be high in family members. Although there is a poor evidence base, treatment with antimuscarinic medication is standard practice worldwide and prompt intervention is recognized as crucial for effectiveness. The identification of risk factors for the development of death rattle would allow for targeted interventions.Design: A case–control study was designed to retrospectively review two hundred consecutive medical records of mainly cancer patients who died in a hospice inpatient setting between 2009–2011. Fifteen potential risk factors including the original factors weight, smoking, final opioid dose and final midazolam dose were investigated. Methods: Binary logistic regression to identify risk factors for death rattle development.Results: Univariate analysis showed death rattle was significantly associated with final Midazolam doses and final opioid doses, length of dying phase and anticholinergic drug load in the pre-terminal phase. In the final logistic regression model only Midazolam was statistically significant and only at final doses of 20 mg/24 hrs or over (OR 3.81 CI 1.41–10.34).Conclusions: Dying patients with a requirement for a high dose of Midazolam have an increased likelihood of developing death rattle.

KW - bronchial secretions, cholinergic antagonists, death rattle, midazolam, nursing, palliative care, respiratory signs and symptoms, respiratory sounds, risk factors, terminal care

U2 - 10.1111/jan.13704

DO - 10.1111/jan.13704

M3 - Article

VL - 74

SP - 1639

EP - 1648

JO - Journal of Advanced Nursing

JF - Journal of Advanced Nursing

SN - 0309-2402

IS - 7

ER -